UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial

Clinical cancer research, 2007-11, Vol.13 (22), p.6696-6702

2007

Volltextzugriff (PDF)

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2416-2423

2011

Volltextzugriff (PDF)

Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

Cancer, 2010-01, Vol.116 (1), p.31-40

2010

Volltextzugriff (PDF)

Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus

International journal of cardiology, 2017-10, Vol.244, p.37-42

2017

Volltextzugriff (PDF)

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

Journal of clinical oncology, 2012-04, Vol.30 (10), p.1100-1106

2012

Volltextzugriff (PDF)

Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

BMJ, 2007-03, Vol.334 (7592), p.514-517

International edition, 2007

Volltextzugriff (PDF)

Diabetes reduces left ventricular ejection fraction--irrespective of presence and extent of coronary artery disease

European journal of endocrinology, 2011-12, Vol.165 (6), p.945-951

2011

Volltextzugriff (PDF)

The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease

European journal of nuclear medicine and molecular imaging, 2005-06, Vol.32 (6), p.674-681

2005

Volltextzugriff (PDF)

Targeted Radiotherapy with Radiolabeled Somatostatin Analogs

Endocrinology and metabolism clinics of North America, 2011-03, Vol.40 (1), p.187-204

2011

Volltextzugriff (PDF)

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Journal of translational medicine, 2013-01, Vol.11 (1), p.17-17, Article 17

2013

Volltextzugriff (PDF)

Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk

JACC. Cardiovascular imaging, 2014-10, Vol.7 (10), p.1001-1010

2014

Volltextzugriff (PDF)

Relationship between the resting heart rate and the extent of coronary artery disease as assessed by myocardial perfusion SPECT

Swiss medical weekly, 2012-08, Vol.142, p.w13660

2012

Volltextzugriff (PDF)

The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study

The Journal of nuclear medicine (1978), 2007-10, Vol.48 (10), p.1620-1625

2007

Volltextzugriff (PDF)

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab (177LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Blood, 2008-11, Vol.112 (11), p.3055-3055

2008

Volltextzugriff (PDF)

Three‐year recurrence‐free survival in a patient with recurrent medulloblastoma after resection, high‐dose chemotherapy, and intrathecal Yttrium‐90‐labeled DOTA0‐D‐Phe1‐Tyr3‐octreotide radiopeptide brachytherapy

Cancer, 2005-02, Vol.103 (4), p.869-873

2005

Volltextzugriff (PDF)

[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer : Long-term Results of a Phase 2 Clinical Trial

Cancer, 2009-05, Vol.115 (10), p.2052-2062

2009

Volltextzugriff (PDF)

Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy

JACC. Cardiovascular imaging, 2014-10, Vol.7 (10), p.1001-1010

2014

Volltextzugriff (PDF)

The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

European journal of nuclear medicine and molecular imaging, 2017-03, Vol.44 (3), p.468-475

2017

Volltextzugriff (PDF)

Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison

European journal of nuclear medicine and molecular imaging, 2006-06, Vol.33 (6), p.730-737

2006

Volltextzugriff (PDF)

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland

Neuroendocrinology, 2011, Vol.93 (3), p.189-196

2011

Volltextzugriff (PDF)

Dreiländertagung in Bregenz: Liebe Kolleginnen und Kollegen, sehr geehrte Damen und Herren

Nuclear medicine, 2011, Vol.50 (2), p.15-15

2011

Volltextzugriff (PDF)

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

Pancreas, 2017-02, Vol.46 (2), p.151-156

2017

Volltextzugriff (PDF)

Prospective Evaluation of an Algorithm for the Functional Assessment of Lung Resection Candidates

American journal of respiratory and critical care medicine, 1999-05, Vol.159 (5), p.1450-1456

1999

Volltextzugriff (PDF)

Grußwort: Basel 2007: From Screening to Staging

Nuclear medicine, 2007-03, Vol.46 (3), p.N21-N21

Müller-Brand, Jan

2007

Volltextzugriff (PDF)

Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic Issues

Journal of Nuclear Medicine, 2017-09, Vol.58 (9), p.1532-1532

2017

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(80)

Sprache

Englisch
(78)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(52)
Life Sciences & Biomedicine
(42)
Middle Aged
(42)
Science & Technology
(42)
Male
(41)
Female
(38)
Aged
(32)
Adult
(29)
Biological And Medical Sciences
(24)
Medical Sciences
(23)
Radiology, Nuclear Medicine & Medical Imaging
(17)
Oncology
(15)
Octreotide - Analogs & Derivatives
(13)
Aged, 80 And Over
(12)
Radionuclide Imaging
(11)
Radiopharmaceuticals - Therapeutic Use
(11)
Cardiovascular System & Cardiology
(10)
Nuclear Medicine
(10)
Adolescent
(9)
Cardiac & Cardiovascular Systems
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

Diabetes reduces left ventricular ejection fraction--irrespective of presence and extent of coronary artery disease

The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease

Targeted Radiotherapy with Radiolabeled Somatostatin Analogs

Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk

Relationship between the resting heart rate and the extent of coronary artery disease as assessed by myocardial perfusion SPECT

The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab (177LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Three‐year recurrence‐free survival in a patient with recurrent medulloblastoma after resection, high‐dose chemotherapy, and intrathecal Yttrium‐90‐labeled DOTA0‐D‐Phe1‐Tyr3‐octreotide radiopeptide brachytherapy

[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer : Long-term Results of a Phase 2 Clinical Trial

Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy

The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison

Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland

Dreiländertagung in Bregenz: Liebe Kolleginnen und Kollegen, sehr geehrte Damen und Herren

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

Prospective Evaluation of an Algorithm for the Functional Assessment of Lung Resection Candidates

Grußwort: Basel 2007: From Screening to Staging

Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic Issues

Suchergebnisse filtern